

3D Cell Culture Market by Product (Scaffolds [Hydrogels, Solid Scaffolds], Scaffold-free [Low Attachment Plates, Microfluidics, Bioprinted]), Application (Cancer, Stem Cell Research, Tissue Engineering), Trends, End User, Region - Global Forecast to 2030

Market Report | 2025-10-06 | 323 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global 3D cell culture market is projected to reach USD 2.26 billion by 2030 from USD 1.18 billion in 2024, at a CAGR of 11.7% during the forecast period. Factors such as increased adoption of 3D cell culture and a rise in funding for 3D cell culture research drive market growth.

<https://mnmimg.marketsandmarkets.com/Images/3d-cell-culture-market-overview.svg>

The scaffold-based 3D cell culture segment accounted for the highest market share in the product market. Based on the product, the 3D cell culture market is segmented into scaffold-based 3D cell cultures, scaffold-free 3D cell cultures, microfluidics-based 3D cell cultures, and magnetic & bioprinted 3D cell cultures. The scaffold-based 3D cell cultures segment accounted for the largest share in 2024. Hydrogels/ECM analogs have emerged as the key contributor to segment growth. Increased demand for hydrogels is raising the focus of key market players on the development and launch of new products in the market. It is also biocompatible and non-toxic, making it ideal for use in research and drug development. The cancer and stem cell research segment accounted for the largest share of the application market in 2024. Based on the application, the market is segmented into cancer & stem cell research, drug discovery & toxicology testing, and tissue engineering & regenerative medicine. Cancer & stem cell segment research accounted for the largest market share in 2024. The increasing prevalence of cancer and significant funding initiatives for cancer research from the government and the private sector are major factors driving the growth of this application segment.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The Asia Pacific region is likely to be the fastest-growing regional market.

The 3D cell culture market is segmented into Europe, Asia Pacific, North America, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to be the fastest-growing regional segment during the forecast period. Growth in this market is attributed to the presence of favorable regulatory guidelines, government support for cell culture-based vaccine production, low manufacturing costs, and the growing focus of global market players on emerging Asian countries. The markets for biologics such as antibodies and protein-based drugs are also on the rise in the Asia Pacific region. Biotechnology-based drugs are anticipated to be one of the key drivers for the research industry due to increased research and government funds provided for these drugs. Global pharmaceutical firms are increasingly moving to Asia to tap into its thriving market and lower their production costs by shifting manufacturing to the region.

The primary interviews conducted for this report can be categorized as follows:

-□By Respondent: Tier 1- 25%, Tier 2- 35%, and Tier 3- 40%

-□By Designation: C-level Executives- 55%, Directors- 20%, and Others- 25%

-□By Region: North America- 45%, Europe- 20%, the Asia Pacific- 20%, Latin America- 10%, the Middle East- 3%, and Africa- 2%

The top players in the global 3D cell culture market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Corning Incorporated (US), Lonza (Switzerland), Tecan Trading AG (Switzerland), Avantor, REPROCELL Inc. (Japan), 3D Biotek LLC. (US), S-BIO, Vaupell Holdings Inc. (US), Advanced BioMatrix Inc. (US), UPM Biomedicals (Finland), SYNTHCON, INCORPORATED (US), Emulate, Inc. (US), CN Bio Innovations Ltd. (UK), Kirkstall Ltd. (UK), Lena Biosciences (US), TissUse GmbH (Germany), Cellendes GmbH (Germany), Greiner Bio-one International GmbH (Germany), AMSBIO (UK), MIMETAS B.V.(Netherlands), and Promocell GmbH (Germany).

Research Coverage

This research report categorizes the 3D cell culture market by product (scaffold-based 3D cell cultures, scaffold-free 3D cell cultures, microfluidics-based 3D cell cultures, and magnetic & bioprinted 3D cell cultures), application (cancer & stem cell research, drug discovery & toxicology testing, and tissue engineering & regenerative medicine), end user (pharmaceutical & biotechnology companies, research institutes, cosmetics industry, and other end users) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the 3D cell culture market. A detailed analysis of the key industry players has been done to provide insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, and acquisitions, and recent developments associated with the 3D cell culture market. This report covers a competitive analysis of top players and upcoming startups in the 3D cell culture market ecosystem.

The report's scope covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the 3D cell culture market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product launches, acquisitions, and recent developments associated with the 3D cell culture market. This report covers the competitive analysis of upcoming startups in the 3D cell culture market ecosystem.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall 3D cell culture market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

-□Analysis of key drivers (high focus on developing alternatives to animal testing, increasing adoption of personalized medicine, increased government support and funding, rising academia-research collaborations), restraints (high cost of implementing 3D

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

cell culture technologies, lack of widely accepted or single standardization in 3D cell culture), opportunities (emergence of microfluidic based 3D cell culture), and challenges (lack of consistency in 3D cell culture products, high dependency on plastic waste disposals and consumables) influencing the growth of 3D cell culture market.

-□Product Development/Innovation: Detailed insights on newly launched products of the 3D cell culture market

-□Market Development: Comprehensive information about lucrative markets - the report analyses the 3D cell culture market across varied regions.

-□Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the 3D cell culture market.

-□Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Corning Incorporated (US), Lonza (Switzerland), and Avantor Inc. (US), among others

Table of Contents:

1	INTRODUCTION	32
1.1	STUDY OBJECTIVES	32
1.2	MARKET DEFINITION	32
1.3	MARKET SCOPE	33
1.3.1	MARKET SEGMENTATION AND REGIONAL SCOPE	33
1.3.2	INCLUSIONS AND EXCLUSIONS	33
1.3.3	YEARS CONSIDERED	34
1.4	CURRENCY CONSIDERED	34
1.5	STAKEHOLDERS	34
1.6	SUMMARY OF STRATEGIC CHANGES	35
2	RESEARCH METHODOLOGY	36
2.1	RESEARCH DATA	36
2.1.1	SECONDARY DATA	37
2.1.1.1	Key sources of secondary data	37
2.1.1.2	Key objectives of secondary research	37
2.1.2	PRIMARY DATA	38
2.1.2.1	Breakdown of primaries	38
2.1.2.2	Key objectives of primary research	39
2.2	MARKET SIZE ESTIMATION	39
2.2.1	GLOBAL MARKET SIZE ESTIMATION	39
2.2.1.1	Revenue share analysis (bottom-up approach)	40
2.2.1.2	Secondary data	41
2.2.1.3	Primary interviews and MnM repository analysis	42
2.2.2	INSIGHTS FROM PRIMARY EXPERTS	42
2.2.3	SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH)	43
2.3	GROWTH RATE PROJECTION	44
2.4	DATA TRIANGULATION	46
2.5	RESEARCH ASSUMPTIONS	47
2.6	RESEARCH LIMITATIONS	48
2.7	RISK ANALYSIS	48
3	EXECUTIVE SUMMARY	49
3.1	KEY INSIGHTS AND MARKET HIGHLIGHTS	49
3.2	STRATEGIC IMPERATIVES FOR STAKEHOLDERS	51
3.3	DISRUPTIVE TRENDS SHAPING MARKET	51

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

3.4	HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS	51
3.5	SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST	52
4	PREMIUM INSIGHTS	53
4.1	UNMET NEEDS AND WHITE SPACES	53
4.2	INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES	53
4.3	EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFTS	53
4.4	STRATEGIC MOVES BY TIER 1/2/3 PLAYERS	54
4.5	VC/PRIVATE EQUITY INVESTMENT TRENDS AND STARTUP LANDSCAPE	54
4.6	SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES	54
5	MARKET OVERVIEW	56
5.1	INTRODUCTION	56
5.2	MARKET DYNAMICS	56
5.2.1	DRIVERS	57
5.2.1.1	High focus on developing alternatives to animal testing	57
5.2.1.2	Growing shift toward personalized medicine	58
5.2.1.3	Integration of microphysiological systems and organ-on-chip platforms	59
5.2.2	RESTRAINTS	60
5.2.2.1	High costs of implementing 3D cell culture technologies	60
5.2.2.2	Absence of widely accepted or unified standards for experimental protocols	60
5.2.3	OPPORTUNITIES	61
5.2.3.1	High growth opportunities and booming biopharmaceutical sector in emerging economies	61
5.2.4	CHALLENGES	61
5.2.4.1	Lack of consistency in scaffold-based 3D cell culture products	61
5.2.4.2	High dependence on plastic waste disposals and consumables	62
5.3	TECHNOLOGY ANALYSIS	63
5.3.1	KEY TECHNOLOGIES	63
5.3.1.1	Microfluidics	63
5.3.1.2	Bioprinting	64
5.3.1.3	Organ-on-chip	64
5.3.2	COMPLEMENTARY TECHNOLOGIES	64
5.3.2.1	High-content imaging and automated microscopy	64
5.3.2.2	High-throughput screening platforms	65
5.3.3	ADJACENT TECHNOLOGIES	65
5.3.3.1	Magnetic levitation	65
5.3.3.2	Microfabrication	65
	?	
5.4	TRADE ANALYSIS	66
5.4.1	IMPORT DATA	66
5.4.2	EXPORT DATA	67
5.5	REGULATORY LANDSCAPE	69
5.5.1	REGULATORY FRAMEWORK	69
5.5.1.1	North America	69
5.5.1.2	Europe	69
5.5.1.3	Asia Pacific	70
5.5.1.4	Latin America	71
5.5.1.5	Middle East & Africa	71
5.5.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	71

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.6	PORTER'S FIVE FORCES ANALYSIS	75
5.6.1	BARGAINING POWER OF SUPPLIERS	76
5.6.2	BARGAINING POWER OF BUYERS	76
5.6.3	THREAT OF NEW ENTRANTS	76
5.6.4	THREAT OF SUBSTITUTES	76
5.6.5	INTENSITY OF COMPETITIVE RIVALRY	77
5.7	IMPACT OF AI/GENERATIVE AI ON 3D CELL CULTURE MARKET	77
5.7.1	INTRODUCTION	77
5.7.2	MARKET POTENTIAL OF AI IN 3D CELL CULTURE APPLICATIONS	77
5.7.3	AI USE CASES	78
5.7.4	KEY COMPANIES IMPLEMENTING AI	78
5.7.5	FUTURE OF GENERATIVE AI IN 3D CELL CULTURE ECOSYSTEM	79
5.8	IMPACT OF 2025 US TARIFF ON 3D CELL CULTURE MARKET	79
5.8.1	INTRODUCTION	79
5.8.2	KEY TARIFF RATES	80
5.8.3	PRICE IMPACT ANALYSIS	81
5.8.4	IMPACT ON COUNTRY/REGION	81
5.8.4.1	US	81
5.8.4.2	Europe	82
5.8.4.3	Asia Pacific	82
5.8.5	IMPACT ON END-USE INDUSTRIES	83
5.8.5.1	Pharmaceutical and biotech companies	83
5.8.5.2	Hospitals and diagnostic laboratories	83
5.8.5.3	Academic and research institutes	84
5.8.5.4	Contract research organizations & contract development and manufacturing organizations	84
	?	
6	INDUSTRY TRENDS	85
6.1	PRICING ANALYSIS	85
6.1.1	AVERAGE SELLING PRICE TREND, BY KEY PLAYER	85
6.1.2	AVERAGE SELLING PRICE TREND, BY REGION	88
6.2	PATENT ANALYSIS	90
6.2.1	METHODOLOGY	90
6.2.2	NUMBER OF PATENTS FILED	91
6.2.3	LIST OF KEY PATENTS	92
6.3	KEY CONFERENCES AND EVENTS, 2025-2026	93
6.4	INVESTMENT AND FUNDING SCENARIO	94
6.5	VALUE CHAIN ANALYSIS	95
6.6	ECOSYSTEM ANALYSIS	97
6.7	KEY STAKEHOLDERS AND BUYING CRITERIA	99
6.7.1	KEY STAKEHOLDERS IN BUYING PROCESS	99
6.7.2	KEY BUYING CRITERIA	100
6.8	TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS	101
7	3D CELL CULTURE MARKET, BY TYPE	103
7.1	INTRODUCTION	104
7.2	SCAFFOLD-BASED 3D CELL CULTURES	104
7.2.1	HYDROGELS/ECM ANALOGS	108
7.2.1.1	Hydrogels/ECM analogs to dominate scaffold-based 3D cell culture market during forecast period	108

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7.2.2	SOLID SCAFFOLDS	111
7.2.2.1	Growing adoption of solid scaffolds in regenerative medicine and preclinical in vitro testing to boost market	111
7.2.3	MICROPATTERNED SURFACES	115
7.2.3.1	Ability of micropatterned surfaces to enhance expression of enzyme levels and drug reactivity to drive growth	115
7.3	SCAFFOLD-FREE 3D CELL CULTURES	118
7.3.1	LOW-ATTACHMENT PLATES	122
7.3.1.1	Low-attachment plates to grow at highest rate in scaffold-free 3D cell cultures market	122
7.3.2	HANGING DROP PLATES	125
7.3.2.1	Growing use of hanging drop plates in stem cell differentiation and cytotoxicity research to propel growth	125
7.3.3	3D BIOREACTORS	129
7.3.3.1	Wide usage of 3D bioreactors in mass production of cells to support market growth	129
7.4	MICROFLUIDICS-BASED 3D CELL CULTURES	132
7.4.1	MICROFLUIDICS-BASED 3D CELL CULTURES TO GROW AT HIGHEST RATE IN 3D CELL CULTURE MARKET DURING FORECAST PERIOD	132
	?	
7.5	MAGNETIC & BIOPRINTED 3D CELL CULTURES	135
7.5.1	GROWING USE OF BIOPRINTING TECHNOLOGIES IN CANCER MODEL CREATION TO BOOST MARKET	135
8	3D CELL CULTURE MARKET, BY APPLICATION	139
8.1	INTRODUCTION	140
8.2	CANCER & STEM CELL RESEARCH	140
8.2.1	INCREASING DEMAND FOR PATIENT-DERIVED, AUTOMATED 3D ORGANOID SYSTEMS TO PROPEL MARKET	140
8.3	DRUG DISCOVERY & TOXICOLOGY TESTING	144
8.3.1	REGULATORY DEMAND AND TECHNOLOGICAL MATURATION OF PREDICTIVE 3D TOXICOLOGY MODELS TO DRIVE MARKET GROWTH	144
8.4	TISSUE ENGINEERING & REGENERATIVE MEDICINE	147
8.4.1	ADVANCEMENTS IN BIOMATERIAL INNOVATION AND SCAFFOLD CUSTOMIZATION TO BOOST MARKET	147
8.5	3D CELL CULTURE MARKET, BY MODEL TYPE	151
9	3D CELL CULTURE MARKET, BY END USER	152
9.1	INTRODUCTION	153
9.2	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	153
9.2.1	GROWING INTEGRATION OF 3D MODELS BY PHARMA AND BIOTECH COMPANIES TO DRIVE MARKET GROWTH	153
9.3	RESEARCH INSTITUTES	157
9.3.1	RESEARCH GRANTS FROM GOVERNMENTAL AND NON-GOVERNMENTAL ORGANIZATIONS TO AUGMENT MARKET	157
9.4	COSMETICS INDUSTRY	161
9.4.1	GROWING FOCUS ON DEVELOPING ALTERNATIVES FOR ANIMAL TESTING TO FUEL MARKET	161
9.5	OTHER END USERS	164
10	3D CELL CULTURE MARKET, BY REGION	168
10.1	INTRODUCTION	169
10.2	NORTH AMERICA	169
10.2.1	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	170
10.2.2	US	174
10.2.2.1	Product launches and capacity expansions to drive market growth	174
10.2.3	CANADA	176
10.2.3.1	Advancements in tissue therapeutics and regenerative medicine to boost market	176
10.3	EUROPE	179
10.3.1	MACROECONOMIC OUTLOOK FOR EUROPE	179
10.3.2	GERMANY	182

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.3.2.1 Strategic acquisitions to fuel market growth 182
- 10.3.3 UK 185
 - 10.3.3.1 Growing government funding and initiatives to propel market growth 185
 - 10.3.4 FRANCE 187
 - 10.3.4.1 Strategic collaborations to propel market growth 187
 - 10.3.5 ITALY 190
 - 10.3.5.1 Strong government support to enhance R&D activities 190
 - 10.3.6 SPAIN 192
 - 10.3.6.1 Strategic R&D investments and collaborative frameworks to drive market 192
 - 10.3.7 REST OF EUROPE 195
 - 10.4 ASIA PACIFIC 197
 - 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 197
 - 10.4.2 CHINA 201
 - 10.4.2.1 Rising pharmaceutical R&D and investments to drive market growth 201
 - 10.4.3 JAPAN 204
 - 10.4.3.1 Strategic collaborations and technological advancements to augment market 204
 - 10.4.4 INDIA 207
 - 10.4.4.1 Strategic collaborations and infrastructure development to support market 207
 - 10.4.5 SOUTH KOREA 209
 - 10.4.5.1 Strategic investments and collaborations to propel market growth 209
 - 10.4.6 AUSTRALIA 212
 - 10.4.6.1 Advancements in 3D cell culture technologies to propel market 212
 - 10.4.7 REST OF ASIA PACIFIC 214
 - 10.5 LATIN AMERICA 217
 - 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 218
 - 10.5.2 BRAZIL 221
 - 10.5.2.1 Rising prevalence of cancer and therapeutic development to support market 221
 - 10.5.3 MEXICO 224
 - 10.5.3.1 Growth in biopharmaceutical market to spur 3D cell culture demand 224
 - 10.5.4 REST OF LATIN AMERICA 226
 - 10.6 MIDDLE EAST 229
 - 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 229
 - 10.6.2 GCC COUNTRIES 232
 - 10.6.2.1 Saudi Arabia 235
 - 10.6.2.1.1 Strategic healthcare initiatives to drive market 235
 - 10.6.2.2 UAE 238
 - 10.6.2.2.1 Developments in healthcare infrastructure and growing government initiatives to drive market 238
 - 10.6.2.3 Rest of GCC Countries 240
 - 10.6.3 REST OF MIDDLE EAST 243
 - ?
 - 10.7 AFRICA 246
 - 10.7.1 STRATEGIC COLLABORATIONS AND HEALTH INITIATIVES TO FUEL MARKET GROWTH 246
 - 10.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 246
 - 11 COMPETITIVE LANDSCAPE 250
 - 11.1 INTRODUCTION 250
 - 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 250
 - 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN 3D CELL CULTURE MARKET 251

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.3	REVENUE ANALYSIS, 2020?2024	253
11.4	MARKET SHARE ANALYSIS, 2024	254
11.5	COMPANY VALUATION AND FINANCIAL METRICS	256
11.5.1	COMPANY VALUATION	256
11.5.2	FINANCIAL METRICS	257
11.6	BRAND/PRODUCT COMPARISON	257
11.7	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024	258
11.7.1	STARS	258
11.7.2	EMERGING LEADERS	258
11.7.3	PERVASIVE PLAYERS	258
11.7.4	PARTICIPANTS	258
11.7.5	COMPANY FOOTPRINT: KEY PLAYERS, 2024	260
11.7.5.1	Company footprint	260
11.7.5.2	Region footprint	261
11.7.5.3	Product footprint	262
11.7.5.4	Application footprint	262
11.7.5.5	End-user footprint	263
11.8	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024	264
11.8.1	PROGRESSIVE COMPANIES	264
11.8.2	RESPONSIVE COMPANIES	264
11.8.3	DYNAMIC COMPANIES	264
11.8.4	STARTING BLOCKS	264
11.8.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024	266
11.8.5.1	Detailed list of key startups/SMEs	266
11.8.5.2	Competitive benchmarking of startups/SMEs	267
11.9	COMPETITIVE SCENARIO	268
11.9.1	PRODUCT LAUNCHES	268
11.9.2	DEALS	269
11.9.3	EXPANSIONS	270
11.9.4	OTHER DEVELOPMENTS	270
	?	
12	COMPANY PROFILES	271
12.1	KEY PLAYERS	271
12.1.1	THERMO FISHER SCIENTIFIC INC.	271
12.1.1.1	Business overview	271
12.1.1.2	Products offered	272
12.1.1.3	Recent developments	274
12.1.1.3.1	Product launches	274
12.1.1.3.2	Deals	274
12.1.1.3.3	Expansions	275
12.1.1.4	MnM view	276
12.1.1.4.1	Key strengths	276
12.1.1.4.2	Strategic choices	276
12.1.1.4.3	Weaknesses and competitive threats	276
12.1.2	MERCK KGAA	277
12.1.2.1	Business overview	277
12.1.2.2	Products offered	278

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.1.2.3 Recent developments 279
- 12.1.2.3.1 Deals 279
- 12.1.2.3.2 Expansions 280
- 12.1.2.4 MnM view 280
- 12.1.2.4.1 Key strengths 280
- 12.1.2.4.2 Strategic choices 280
- 12.1.2.4.3 Weaknesses and competitive threats 280
- 12.1.3 CORNING INCORPORATED 281
- 12.1.3.1 Business overview 281
- 12.1.3.2 Products offered 282
- 12.1.3.3 Recent developments 283
- 12.1.3.3.1 Product launches 283
- 12.1.3.4 MnM view 284
- 12.1.3.4.1 Key strengths 284
- 12.1.3.4.2 Strategic choices 284
- 12.1.3.4.3 Weaknesses and competitive threats 284
- 12.1.4 LONZA 285
- 12.1.4.1 Business overview 285
- 12.1.4.2 Products offered 286
- 12.1.4.3 Recent developments 287
- 12.1.4.3.1 Product launches 287
- 12.1.4.4 MnM view 287
- 12.1.4.4.1 Key strengths 287
- 12.1.4.4.2 Strategic choices 287
- 12.1.4.4.3 Weaknesses and competitive threats 287
- ?
- 12.1.5 AVANTOR, INC. 288
- 12.1.5.1 Business overview 288
- 12.1.5.2 Products offered 289
- 12.1.6 TECAN TRADING AG 290
- 12.1.6.1 Business overview 290
- 12.1.6.2 Products offered 291
- 12.1.6.3 MnM view 292
- 12.1.6.3.1 Key strengths 292
- 12.1.6.3.2 Strategic choices 292
- 12.1.6.3.3 Weaknesses and competitive threats 292
- 12.1.7 REPROCELL INC. 293
- 12.1.7.1 Business overview 293
- 12.1.7.2 Products offered 293
- 12.1.7.3 Recent developments 295
- 12.1.7.3.1 Deals 295
- 12.1.8 3D BIOTEK LLC 296
- 12.1.8.1 Business overview 296
- 12.1.8.2 Products offered 296
- 12.1.9 EMULATE, INC. 297
- 12.1.9.1 Business overview 297
- 12.1.9.2 Products offered 297

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.1.9.3	Recent developments	298
12.1.9.3.1	Product launches	298
12.1.10	SYNTHECON, INCORPORATED	299
12.1.10.1	Business overview	299
12.1.10.2	Products offered	299
12.1.11	INSPHERO	301
12.1.11.1	Business overview	301
12.1.11.2	Products offered	301
12.1.11.3	Recent developments	302
12.1.11.3.1	Deals	302
12.1.11.3.2	Other developments	302
12.1.12	KIRKSTALL LTD.	303
12.1.12.1	Business overview	303
12.1.12.2	Products offered	303
12.1.13	GREINER BIO-ONE INTERNATIONAL GMBH	304
12.1.13.1	Business overview	304
12.1.13.2	Products offered	304
12.1.14	PROMOCELL GMBH	305
12.1.14.1	Business overview	305
12.1.14.2	Products offered	305
?		
12.1.15	UPM	306
12.1.15.1	Business overview	306
12.1.15.2	Products offered	306
12.2	OTHER PLAYERS	307
12.2.1	CN BIO INNOVATIONS LTD.	307
12.2.2	TISSUSE GMBH	308
12.2.3	LENA BIOSCIENCES	309
12.2.4	CELLENDES GMBH	310
12.2.5	ADVANCED BIOMATRIX, INC. (PART OF BICO)	311
12.2.6	SYNVIVO, INC.	312
12.2.7	AMS BIOTECHNOLOGY (EUROPE) LTD	313
12.2.8	MIMETAS B.V.	314
12.2.9	S-BIO, VAUPELL HOLDINGS INC.	315
12.2.10	NANOFIBER SOLUTIONS	315
13	APPENDIX	316
13.1	DISCUSSION GUIDE	316
13.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	319
13.3	CUSTOMIZATION OPTIONS	321
13.4	RELATED REPORTS	321
13.5	AUTHOR DETAILS	322

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

3D Cell Culture Market by Product (Scaffolds [Hydrogels, Solid Scaffolds], Scaffold-free [Low Attachment Plates, Microfluidics, Bioprinted]), Application (Cancer, Stem Cell Research, Tissue Engineering), Trends, End User, Region - Global Forecast to 2030

Market Report | 2025-10-06 | 323 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

2026-06-09

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com